Anavex Life Sciences Corp (AVXL)

[Doc328]

I'm very happy to hear the peer reviewed paper was accepted, .

If this is the peer reviewed paper Missling talked about at the annual meeting, then this is very disappointing. The article referenced today is a third party review article about S1R mechanism. Notice the generic sentence highlighted. Anavex is referenced AMONG the relevant S1R ligands. A273 has been mentioned several times in the past in other review articles. They will get a couple generic sentences like 'A273 is in trials for AD, PDD and Rett'.

Does this mean that the real peer reviewed article he talked about earlier this year discussing the 2a trial was turned down and needs to be re-written?


From Anavex today

A recent peer-reviewed scientific publication titled, Neuronal Sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases, details the mechanism of action of Sigma-1 receptors (S1R) and references ANAVEX®2-73 among the relevant S1R ligands. The paper summarizes: “In conclusion, S1R is incredibly versatile in its ability to foster neuronal homeostasis in the context of several neurodegenerative disorders.”5